Pharmacovigilance in Saudi Arabia: A Narrative Review on Adverse Drug Reaction Reporting

Hana  J. Al Khabbaz

doi:10.26452/ijrps.v14i4.4452

Hana J. Al Khabbaz ⁽¹⁾

(1) College of Pharmacy, Riyadh Elm University. P.O. Box. 84891, Riyadh, 11681, Saudi Arabia, Saudi Arabia

https://doi.org/10.26452/ijrps.v14i4.4452

Issue
Vol. 14 No. 4 (2023): Volume 14 Issue 4

Keywords:

Adverse Drug Reaction, Pharmacovigilance, Post-Marketing Surveillance, Saudi Food and Drug Authority, Saudi Vigilance System

PDF LaTeX HTML ePUB

Abstract

Adverse drug reaction (ADR) reporting is an important aspect of pharmacovigilance (PV) in ensuring drug safety during the post-marketing surveillance phase. Currently, the National Pharmacovigilance Center (NPC) established by the Saudi Food and Drug Authority (SFDA) is the regulatory authority receiving ADR reports in Saudi Arabia. Spontaneous ADR reports from healthcare professionals and the public are received by the NPC through an electronic platform known as the Saudi Vigilance System. Signal analysis of the received ADR reports aids the decision-making initiatives related to the reported drugs. Stakeholders’ contribution to ADR reporting, and implementation of effective electronic platforms are important factors affecting the national PV performance. The concept of stakeholders reporting on ADR is relatively new in Saudi Arabia, especially to the public. In this narrative review the national studies describing the stakeholders’ knowledge, perception and barriers toward ADR reporting, and the incidence of ADR reporting by healthcare institutions in Saudi Arabia were evaluated. The findings indicate that more efforts are needed by the SFDA to educate stakeholders about the importance of ADR reporting. The study recommends ADR electronic systems integration between the SFDA and healthcare institutions to improve the frequency and quality of ADR reports, and regular feedback on decisions made about ADR reports should be provided by the SFDA to stakeholders to improve their awareness of the importance of ADR reporting and enhance their contribution to PV and ADR reporting process.

Full text article

Generated from XML file

References

X Tan. Investigation of the characteristics of medication errors and adverse drug reactions using pharmacovigilance data in China. Saudi Pharm J, 28(10):1190–1196, 2020.

M A Hadi. Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract, 6:91–98, 2017.

T M Alshammari, M Alshakka, and H Aljadhey. Pharmacovigilance system in Saudi Arabia. Saudi Pharm J, 25(3):299–305, 2017.

A Alharf. Saudi Vigilance Program: Challenges and lessons learned. Saudi Pharm J, 26(3):388– 395, 2018.

S A Bawazir. Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction. SPJ-Saudi Pharmaceutical Journal, 14(1):75–83, 2006.

A El-Metwally. Current status, and future prospects of pharmaco-epidemiology and post-marketing surveillance in Saudi Arabia: A review of literature. Saudi Pharm J, 26(5):629–633, 2018.

C Biagi. Underreporting in pharmacovigi- lance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol, 69(2):237–281, 2013.

T M Alshammari. Completeness of adverse drug reactions reports of the Saudi adverse event reporting system. Saudi Med J, 36(7):821–829, 2015.

H Aljadhey. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. Saudi Med J, 36(9):1097–102, 2015.

T M Alshammari. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. Int J Clin Pharm, 37(6):1104–1114, 2015.

N B Almandil. Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi Med J, 37(12):1359–1364, 2016.

K Moinuddin. Knowledge and Attitude of Health-Care Professionals Toward Adverse Drug Reactions Reporting at King Saud Medical City. J Pharm Bioallied Sci, 10(1):29–34, 2018.

T M Alshammari and M J Almoslem. Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: A multi-centre cross-sectional study. Saudi Pharm J, 26(7):925–931, 2018.

M D Ali. Knowledge, Practice and Attitudes Toward Pharmacovigilance and Adverse Drug Reactions Reporting Process Among Health Care Providers in Dammam, Saudi Arabia. Curr Drug Saf, 13(1):21–25, 2018.

T M Khan. Community pharmacists’ knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia. Ther Adv Drug Saf, 4(2):45–51, 2013.

M A Mahmoud. Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J, 22(5):411–419, 2014.

A Y Aldryhim. Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Expert Opin Drug Saf, 18(8):745–752, 2019.

A Al-Mutairi. Medication safety knowledge, attitude, and practice among hospital pharmacists in tertiary care hospitals in Saudi Arabia: a multi-center study. 79:130–130, 2021.

M Y Alsheikh and M M Alasmari. A National Survey of Community Pharmacists’ Viewpoints About Pharmacovigilance and Adverse Drug Reaction Reporting in Saudi Arabia. Front Pharmacol, 13:819551–819551, 2022.

A M Alshabi. Knowledge, attitude and practice of hospital pharmacists towards pharmacovigilance and adverse drug reaction reporting in Najran, Saudi Arabia. Saudi Pharm J, 30(7):1018–1026, 2022.

S Abdulsalim. Evaluation of Knowledge, Attitudes, and Practices about Pharmacovigilance among Community Pharmacists in Qassim, Saudi Arabia. Int J Environ Res Public Health, 20(4), 2023.

Y Alghazwani. The perspective of pharmacist on pharmacovigilance and adverse drug reaction reporting in Asir region, Saudi Arabia. Eur Rev Med Pharmacol Sci, 27(4):1667–1680, 2023.

N Alkayyal, E Cheema, and M A Hadi. Perspec- tive of Saudi undergraduate pharmacy students on pharmacovigilance and adverse drug reaction reporting: A National Survey. Curr Pharm Teach Learn, 9(5):779–785, 2017.

M Alwhaibi. Pharmacovigilance in healthcare education: students’ knowledge, attitude and perception: a cross-sectional study in Saudi Arabia. BMC Med Educ, 20(1):210–210, 2020.

D Alshayban, M M Islam, M A Alshammari, S Alsulaiman, and D. Pharmacovigilance Perception and Knowledge Among Pharmacists and Interns in Saudi Arabia. Risk Manag Healthc Policy, 13:55–61, 2020.

I Sales. Public awareness and perception toward Adverse Drug Reactions reporting in Riyadh, Saudi Arabia. Saudi Pharm J, 25(6):868–872, 2017.

M A Islam. Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia.

L M Kassem. Understanding Patient Needs Regarding Adverse Drug Reaction Reporting Smartphone Applications: A Qualitative Insight from Saudi Arabia. Int J Environ Res Public Health, 18(8), 2021.

L M Khan. Impact of pharmacovigilance on adverse drug reactions reporting in hospital- ized internal medicine patients at Saudi Ara- bian teaching hospital. Saudi Medical Journal, 33(8):863–868, 2012.

L M Khan, S E Al-Harthi, and O I Saadah. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J, 21(3):261–267, 2013.

R A Almubark. National Cross-Sectional Study of Community-Based Adverse Drug Reactions in Saudi Arabia. Drugs Real World Outcomes, 7(2):161–170, 2020.

L C Esba and G Mardawi. Adverse Drug Reactions Spontaneously Reported at a Tertiary Care Hospital and Preventable Measures Implemented. 46:460–469, 2021.

B Alshehail. Incidence and risk factors of adverse drug reactions in patients with coronavirus disease 2019: A pharmacovigilance experience utilizing an ADR trigger tool. Saudi Pharm J, 30(4):407–413, 2022.

E Al-Shareef and L M Khan. Detection of Adverse Drug Reactions in COVID-19 Hospitalized Patients in Saudi Arabia: A Retrospective Study by ADR Prompt Indicators. pages 11–11, 2023.

N Bin Yousef. Patterns of adverse drug reactions (ADRs) in Saudi Arabia. Saudi Pharm J, 30(1):8–13, 2022.

K A Alenzi. The evaluation of adverse drug reactions in Saudi Arabia: A retrospective observational study. Saudi Pharm J, 2022, 30(6):735–741.

P I Roberts, D J Wolfson, and T G Booth. The role of pharmacists in adverse drug reaction reporting. Drug Saf, 11(1):7–11, 1994.

E Cheema. Assessing the impact of structured education on the knowledge of hospital pharmacists about adverse drug reactions and reporting methods in Saudi Arabia: an open-label randomised controlled trial. Drugs Ther Perspect, 35(6):296–300, 2019.

H Patel. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics. BMC Clinical Pharmacology, 7(1):9–9, 1998.

H Alsaleh and T M Alshammari. Direct healthcare professional communications: A quantitative assessment study. 2021:763–763.

S Ali. Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Ther Adv Drug Saf, 9(10):585–590, 2018.

H S L Jim, A I Hoogland, and N C Brownstein. Innovations in research and clinical care using patient-generated health data. 70:182–199, 2020.

V K Patadia. Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction. Front Pharmacol, 9:594–594, 2018.

R M Lynn, K Riding, and N Mcintosh. The use of electronic reporting to aid surveillance of ADRs in children: a proof of concept study. Arch Dis Child, 95(4):262–267, 2010.

A Ortega. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Ann Pharmacother, 42(10):1491–1497, 2008.

Authors

Hana J. Al Khabbaz

College of Pharmacy, Riyadh Elm University. P.O. Box. 84891, Riyadh, 11681, Saudi Arabia

Hana.Alkhabbaz@riyadh.edu.sa (Primary Contact)

J. Al Khabbaz, H. . (2023). Pharmacovigilance in Saudi Arabia: A Narrative Review on Adverse Drug Reaction Reporting. International Journal of Research in Pharmaceutical Sciences, 14(4), 175–189. https://doi.org/10.26452/ijrps.v14i4.4452